Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation

Mary Garvey

DOI: https://doi.org/10.3390/biomedicines12040740

IF: 4.757

2024-03-27

Biomedicines

Abstract:The human gastrointestinal tract houses a diverse range of microbial species that play an integral part in many biological functions. Several preclinical studies using germ-free mice models have demonstrated that the gut microbiome profoundly influences carcinogenesis and progression. Colorectal cancer appears to be associated with microbial dysbiosis involving certain bacterial species, including F. nucleatum, pks+ E. coli, and B. fragilis, with virome commensals also disrupted in patients. A dysbiosis toward these pro-carcinogenic species increases significantly in CRC patients, with reduced numbers of the preventative species Clostridium butyicum, Roseburia, and Bifidobacterium evident. There is also a correlation between Clostridium infection and CRC. F. nucleatum, in particular, is strongly associated with CRC where it is associated with therapeutic resistance and poor outcomes in patients. The carcinogenic mode of action of pathogenic bacteria in CRC is a result of genotoxicity, epigenetic alterations, ROS generation, and pro-inflammatory activity. The aim of this review is to discuss the microbial species and their impact on colorectal cancer in terms of disease initiation, progression, and metastasis. The potential of anticancer peptides as anticancer agents or adjuvants is also discussed, as novel treatment options are required to combat the high levels of resistance to current pharmaceutical options.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the impact of gut microbiota imbalance (i.e., dysbacteriosis) on the occurrence, development, and disease remission of colorectal cancer (CRC). Specifically, the paper focuses on the following aspects:

1. **Relationship between microbiota and colorectal cancer**: The paper discusses in detail the increase of specific bacterial species (such as F. nucleatum, pks+ E. coli, and B. fragilis) in colorectal cancer patients and how these bacteria promote the development of cancer through mechanisms such as genotoxicity, epigenetic changes, reactive oxygen species (ROS) generation, and pro - inflammatory activities.

2. **Mechanisms of microbiota imbalance**: The paper analyzes how microbiota imbalance affects the occurrence and development of colorectal cancer by producing toxins, triggering chronic inflammation, and changing the cell cycle process. For example, F. nucleatum induces inflammation by expressing FadA and Fap2 adhesins, activates pro - inflammatory cytokines IL - 6 and IL - 8, and thus promotes tumor growth and metastasis.

3. **Exploration of treatment strategies**: The paper also explores new treatment strategies for colorectal cancer, especially the possibility of preventing or treating colorectal cancer by regulating the host's gut microbiota. This includes using prebiotics and probiotics, fecal microbiota transplantation (FMT) and other methods to restore a healthy gut microbiota, so as to reduce inflammation and lower cancer risk.

4. **Combination of microbiota and immunotherapy**: The paper also mentions that the regulation of microbiota can be combined with new immunotherapy methods such as immune checkpoint inhibitors (ICIs) and CAR - T cell therapy to improve the treatment effect.

In summary, this paper aims to comprehensively analyze the role of gut microbiota imbalance in the occurrence and development of colorectal cancer and explore new strategies for preventing and treating colorectal cancer by regulating the gut microbiota.